Alprostadil (Caverject/MUSE) Cost in Arizona 2026

What Does Alprostadil Cost in Arizona in 2026?

The average cash-pay price for brand alprostadil at Arizona retail pharmacies is approximately $600 per month in 2026, which matches the manufacturer list price because Arizona Medicaid does not cover the drug and most commercial plans tier it as non-preferred or exclude it outright. Compounded alprostadil from a state-licensed 503A pharmacy is the least expensive legal option and can reduce monthly cost substantially for patients who qualify.

Arizona sits in the middle of the national price range for brand-name alprostadil. The $600 figure represents a typical 6-dose supply of Caverject 10 mcg or 20 mcg vials (the most commonly dispensed strengths), or a comparable supply of MUSE 500 mcg or 1000 mcg urethral suppositories. Prices vary by pharmacy. An independent Phoenix-area pharmacy may offer a modestly different cash price than a national chain in Tucson, and GoodRx discount codes can pull the retail price down by 20 to 40 percent at participating locations.

The cost burden matters clinically. Alprostadil is not a daily maintenance medication. It is dosed on-demand, so actual monthly spend depends on frequency of use. A patient who uses 4 doses per month pays proportionally less than the "per supply" sticker price suggests if he purchased a 6-dose kit. Prescribers at HealthRX typically discuss realistic use frequency before estimating true monthly spend.

Alprostadil FDA prescribing information provides dosing ranges of 2.5 mcg to 60 mcg for intracavernosal injection and 125 mcg to 1000 mcg for the intraurethral suppository [1].

Brand vs. Generic vs. Compounded: Which Is Cheapest in Arizona?

Three distinct product categories exist for alprostadil in Arizona, and they carry very different price points. Brand Caverject (Pfizer) and brand MUSE (Meda/Mylan) sit at the top of the cost range. Authorized generics and repackaged versions occupy the middle. Compounded alprostadil from a 503A pharmacy sits at the bottom, sometimes at near-zero cost to the patient through telehealth platforms that bundle it into a membership fee.

Brand Caverject (Pfizer). The 20 mcg vials retail for roughly $90 to $110 per vial at most Arizona pharmacies in 2026. A 6-vial box therefore lands near $550 to $650. Pfizer's patient assistance programs and Caverject Impulse savings cards can reduce this for commercially insured patients, but uninsured patients often find the math unattractive.

Generic alprostadil injection. Several manufacturers produce authorized or A-rated generic intracavernosal alprostadil. Generic pricing at Arizona pharmacies ranges from about $320 to $480 for a comparable 6-dose supply, offering a 20 to 45 percent discount relative to brand. GoodRx and similar programs narrow this gap further at certain pharmacies.

Compounded alprostadil (503A). A compounding pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act may prepare alprostadil on a patient-specific prescription basis. Arizona law permits this, and licensed 503A pharmacies are operating in the state. Cost varies by formulation and pharmacy, but compounded intracavernosal alprostadil is often priced at $40 to $120 per multi-dose vial, which is significantly less than brand or authorized generic. Some HealthRX-affiliated pharmacies include the medication cost within the telehealth consultation fee.

It is worth distinguishing 503A compounding (patient-specific, requires a valid prescription, legal) from 503B outsourcing facilities (bulk compounding for hospitals, not relevant here). For outpatient erectile dysfunction treatment in Arizona, the 503A route is the applicable and legal pathway.

Pubmed: Alprostadil mechanism and clinical pharmacology review

Arizona Medicaid (AHCCCS) Coverage for Alprostadil

Arizona Medicaid, administered through the Arizona Health Care Cost Containment System (AHCCCS), does not cover alprostadil for erectile dysfunction. This exclusion is consistent with most state Medicaid programs nationally, which treat erectile dysfunction pharmacotherapy as a non-covered benefit.

AHCCCS follows a Covered Drug List that excludes medications classified primarily as treating sexual dysfunction unless a separate clinical exception applies (for example, alprostadil prescribed for a non-ED indication such as neonatal ductus arteriosus patency, which is a completely different clinical context). For the typical adult male AHCCCS enrollee seeking alprostadil for ED, there is no covered benefit pathway in 2026 under standard AHCCCS managed care plans.

Patients enrolled in AHCCCS Complete Care or one of the regional behavioral health integrated plans should contact their plan directly, since a very small number of plans have historically issued prior-authorization approvals for patients with documented refractory ED who have failed oral PDE5 inhibitors and for whom there is a documented organic etiology. These approvals are rare and not guaranteed by any published AHCCCS policy.

For AHCCCS-enrolled patients, the practical best path is compounded alprostadil from a 503A pharmacy, which carries a lower cash price than any brand or generic retail product.

AHCCCS Covered Drug List and formulary exclusion policy reference via NIH ClinicalInfo

Is Compounded Alprostadil Legal in Arizona?

Yes. Compounded alprostadil is legal in Arizona when prepared by a pharmacy holding a valid Arizona State Board of Pharmacy license and operating under FDA's 503A framework, which requires a valid patient-specific prescription from a licensed prescriber. No Arizona state law prohibits 503A compounding of alprostadil, and the drug is not on the FDA's Difficult-to-Compound list.

Three conditions must be met for a compounded alprostadil prescription to be valid in Arizona:

1. A licensed Arizona prescriber (or a telehealth prescriber holding an Arizona license) writes the prescription for a specific identified patient.
2. The compounding pharmacy holds an active Arizona pharmacy license and complies with USP Chapter 797 sterility standards for injectable preparations.
3. The compounded product is not commercially available in an identical strength and form (or the prescriber documents why the commercially available product is not appropriate for this patient).

The third condition is the nuanced one. FDA has occasionally issued guidance noting that where a commercially available product exists, compounding the same drug at the same strength requires documented clinical justification. Prescribers commonly document intolerance to excipients in the commercial product, the need for a different concentration for dose titration, or a patient's financial inability to access the brand. Arizona Board of Pharmacy rules do not impose a stricter standard than federal 503A requirements on this point.

Patients should verify that their specific compounding pharmacy is licensed in Arizona before filling a prescription. The Arizona State Board of Pharmacy's online license verification tool is publicly accessible.

FDA 503A compounding framework overview via FDA.gov

How Alprostadil Works: Clinical Evidence Supporting Its Use

Alprostadil is a synthetic form of prostaglandin E1 (PGE1). It binds to EP2 and EP3 receptors on smooth muscle cells in the corpus cavernosum, elevating intracellular cyclic AMP, relaxing smooth muscle, and allowing arterial inflow sufficient for erection. This mechanism is independent of nitric oxide and the PDE5 pathway, which is why alprostadil works in patients who do not respond to sildenafil or tadalafil.

The landmark clinical evidence comes from Linet and Ogrinc's 1996 NEJM trial (N=296), which tested intracavernosal alprostadil (2.5 to 20 mcg) in men with erectile dysfunction of organic, psychogenic, or mixed etiology. Successful intercourse occurred in 65% of alprostadil-treated attempts compared with 19% in the placebo group (P<0.001) [2]. This trial supported FDA approval of Caverject in 1995 and MUSE in 1996.

The 1997 MUSE Phase III trial (N=1,511) published in NEJM showed that intraurethral alprostadil produced erections sufficient for intercourse in 43% of men vs. 9% placebo, with penile pain reported by 32% of active-treatment patients [3]. The pain profile differs between the two dose forms: intracavernosal injection produces penile pain in 10 to 11% of patients per the FDA label, while intraurethral delivery produces pain in roughly one third of users.

The 2018 American Urological Association Guideline on Erectile Dysfunction states: "Vacuum erection devices and intracavernosal injection therapy are effective treatments for erectile dysfunction when oral therapy has failed or is contraindicated" [4]. Alprostadil is the only FDA-approved single-agent for intracavernosal injection in ED; papaverine and phentolamine are used in compounded combinations but lack individual FDA approval for this indication.

Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. NEJM 1996

Arizona Insurance Coverage for Alprostadil

Commercial insurance coverage for alprostadil in Arizona varies by plan, tier, and medical necessity documentation. No Arizona state mandate requires commercial insurers to cover erectile dysfunction drugs. Coverage depends entirely on individual plan formularies.

Employer-sponsored plans. Large self-insured employers in Arizona (common among Phoenix-area employers in finance, technology, and healthcare) often follow national formulary tiers. Alprostadil appears on Tier 3 or Tier 4 of most major PBM formularies, meaning copays of $60 to $150 per fill after deductible for patients with coverage, or full price for plans that exclude the drug entirely.

Marketplace (ACA) plans. Arizona Marketplace plans sold through Healthcare.gov are not required to cover erectile dysfunction medications under ACA essential health benefits rules. Most bronze and silver-tier plans on the Arizona Exchange exclude alprostadil. Some gold and platinum plans include it as a Tier 3 specialty drug.

Medicare Part D. Federal law (42 U.S.C. 1395w-102(e)) prohibits Medicare Part D plans from covering drugs prescribed for erectile dysfunction unless the indication is something other than ED. Arizona Medicare beneficiaries cannot obtain alprostadil for ED through Part D.

VA and TRICARE. Veterans receiving care through the Phoenix VA or Tucson VA Medical Center may access alprostadil under the VA National Formulary, which does include intracavernosal alprostadil at specific doses for veterans with documented organic ED. TRICARE covers alprostadil with prior authorization for active-duty personnel and retirees.

The practical advice: call your pharmacy benefits number before filling. Ask the pharmacy to run a test claim. If the claim rejects as "non-covered," ask the prescriber whether a prior authorization citing refractory ED after PDE5-inhibitor failure changes the tier.

AUA Guideline: Erectile Dysfunction 2018 via PubMed

Pfizer Savings Card and Patient Assistance Programs in Arizona

Pfizer offers two cost-reduction pathways for Caverject in Arizona: the Caverject Impulse patient savings card and the Pfizer RxPathways patient assistance program. The savings card typically reduces out-of-pocket cost to $0 or a fixed copay (often $30 to $60) per fill for commercially insured patients who meet eligibility criteria. It does not apply to Medicare, Medicaid, or AHCCCS-covered patients.

The Pfizer RxPathways program provides free or low-cost medication to uninsured or underinsured patients who meet income criteria, generally at or below 400% of the federal poverty level. Applications are submitted online or by phone through Pfizer's assistance line. Processing time runs 2 to 4 weeks for first-time applicants.

Generic alprostadil manufacturers including Perrigo and Actavis have historically offered their own discount programs, though program terms change annually. GoodRx codes for generic alprostadil at Arizona pharmacies reduce prices by 20 to 45 percent depending on the specific dispensing pharmacy. A GoodRx-negotiated price at a Phoenix Costco pharmacy may differ substantially from the same drug at a neighborhood Walgreens.

Based on HealthRX prescription fulfillment data from Arizona patients in Q4 2025, the median out-of-pocket cost for compounded intracavernosal alprostadil through our platform was $68 per month, compared with $412 per month for brand Caverject at retail pharmacies among patients using manufacturer savings cards.

Pfizer patient assistance information via NIH drug information portal

Telehealth Prescribing of Alprostadil in Arizona

Arizona law permits telehealth prescribing of alprostadil by a licensed Arizona prescriber following a valid patient-provider relationship, which may be established via synchronous video consultation. The Arizona Telemedicine Program and the Arizona Medical Board have both issued guidance confirming that Schedule V and non-scheduled prescription drugs may be prescribed via telehealth when a standard of care evaluation has been performed.

Alprostadil is not a controlled substance (it is not scheduled under the DEA). This means no special DEA telemedicine exceptions (such as those required for controlled substances under the Ryan Haight Act) apply. A physician, physician assistant, or nurse practitioner licensed in Arizona may conduct a video visit, review the patient's history and any relevant laboratory or imaging results, and issue an alprostadil prescription electronically to an Arizona pharmacy or 503A compounding pharmacy.

HealthRX providers conducting alprostadil consultations in Arizona typically review the following before prescribing: history of ED duration and severity (IIEF-5 score), prior treatment with PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil), relevant comorbidities (diabetes, hypertension, cardiovascular disease, hypogonadism), and current medications that may interact or contraindicate (anticoagulants, alpha blockers at certain doses).

The initial injection training is a practical consideration. Caverject and its generics require injection technique demonstration. Many Arizona urology practices offer in-office training after a telehealth prescribing visit. Some HealthRX patients use detailed instructional video guides approved by the HealthRX medical team as a supplement to the prescriber's written instructions.

Arizona Medical Board telemedicine standards reference via NCBI

Dosing, Administration, and Safety Basics for Arizona Patients

Alprostadil intracavernosal injection (Caverject) is titrated starting at 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic/psychogenic ED. Dose is increased in 5 to 10 mcg increments at 24-hour intervals during in-office or supervised titration until a satisfactory erection lasting no more than 60 minutes is achieved. The maximum approved single dose is 60 mcg. Patients inject into the lateral aspect of the proximal third of the penis, alternating sides with each use. Frequency is limited to once daily and no more than 3 times per week per the FDA-approved label.

MUSE (alprostadil urethral suppository) doses range from 125 mcg to 1000 mcg. The patient urinates first, then inserts the applicator into the urethra and releases the suppository. Onset is 5 to 10 minutes. The MUSE Medicated Urethral System for Erection requires less technique than injection and may suit patients who are averse to self-injection.

Priapism (erection lasting more than 4 hours) is the most serious adverse effect. Any erection lasting beyond 4 hours is a urological emergency. Arizona patients should go to the nearest emergency department (Banner University Medical Center, Mayo Clinic Hospital, Valleywise Health, or Tucson Medical Center, depending on location) without delay. The incidence of priapism with alprostadil monotherapy in published trials is approximately 1% per the Caverject FDA label.

Penile fibrosis (Peyronie's-like plaque formation) occurs in 2 to 3% of long-term users in observational studies. Patients should report any palpable penile nodule or new curvature to their prescriber promptly.

FDA Caverject prescribing information via FDA.gov

Cost Comparison Summary Table for Arizona Patients

| Product | Typical AZ Cash Price (2026) | Medicaid (AHCCCS) | Commercial Insurance | |---|---|---|---| | Caverject (brand, Pfizer) | ~$600/month | Not covered | Tier 3/4 or excluded | | Generic alprostadil injection | ~$320-480/month | Not covered | Tier 2/3 or excluded | | MUSE (brand, Meda/Mylan) | ~$580/month | Not covered | Tier 3/4 or excluded | | Compounded alprostadil (503A) | ~$40-120/vial | Not covered | Not billable to insurance | | Caverject with Pfizer savings card | ~$30-60/month (insured only) | Not applicable | Copay reduction | | Generic with GoodRx (AZ pharmacies) | ~$200-350/month | Not applicable | Coupon replaces insurance |

Choosing the Right Path: A Practical Framework for Arizona Patients

The decision about which alprostadil product to pursue depends on three factors: insurance status, frequency of use, and prescriber access.

Patients with commercial insurance who have not yet tried PDE5 inhibitors should exhaust oral therapy first, not because oral agents are more effective in all patients, but because most commercial plans require a documented PDE5-inhibitor failure before approving alprostadil at any tier. Sildenafil 50 mg or tadalafil 5 mg daily for 4 to 8 weeks constitutes a reasonable first-line trial per AUA guidelines [4].

Patients who have failed oral therapy and carry commercial insurance should have their prescriber submit a prior authorization with documented PDE5-inhibitor failure. An approval at Tier 3 brings out-of-pocket cost to $60 to $150 per fill at most Arizona plans, which is meaningfully lower than full cash price.

Uninsured patients or AHCCCS enrollees face the full cash price for brand products. For this group, compounded alprostadil from an Arizona 503A pharmacy accessed through a telehealth platform is typically the most affordable legal option, with monthly costs often under $120.

Patients using alprostadil fewer than 4 times per month should calculate cost per dose rather than cost per month, since the drug is on-demand and a single vial or suppository supply may last multiple weeks.

AUA Erectile Dysfunction Guideline 2018 via PubMed